Truist Securities maintains Lemonade at Buy, lowers price target to $60 from $70
Truist Securities kept Lemonade at Buy but reduced its price target from $70 to $60, a 14.3% cut. This implies a 44.6% upside from the Nov 5 close of $41.48, according to the firm.
How this was made
The 30-second read
Why it matters
The target reduction may trigger short‑term selling pressure, but longer‑term fundamentals could differ.
Market read
Analyst target cut is a modest catalyst for LMND, likely influencing short‑term price action.
What to watch
Potential upside from upcoming product launches or regulatory changes not reflected in the target.
Background
Lemonade (LMND) is a US‑listed insurtech company. The price target change is the primary new fact in the article.
Ticker impact
Truist Securities lowered Lemonade's price target to $60 from $70, indicating a bearish outlook.
likely downside pressure as investors price in the lower target
Target reduction signals reduced upside expectations, which may prompt short‑term selling.
Market effects
May weigh on other insurtech stocks as analysts reassess valuations.
Limited to US market participants focused on fintech.
Low global impact.
Counterpoint
Some investors may view the cut as an entry point if they believe the market overreacted.
Key entities
- analystTruist Securities
Equity research firm issuing the rating and target update.
- companyLemonade
US‑listed insurtech firm (ticker LMND).
